Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 07, 2023

Patritumab Deruxtecan for EGFR-Mutated NSCLC After EGFR TKI Therapy and Platinum-Based Chemotherapy

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
J. Clin. Oncol 2023 Sep 10;[EPub Ahead of Print], HA Yu, Y Goto, H Hayashi, E Felip, J Chih-Hsin Yang, M Reck, K Yoh, SH Lee, L Paz-Ares, B Besse, P Bironzo, DW Kim, ML Johnson, YL Wu, T John, S Kao, T Kozuki, E Massarelli, J Patel, E Smit, KL Reckamp, Q Dong, P Shrestha, PD Fan, P Patel, A Sporchia, DW Sternberg, D Sellami, PA Jänne

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading